A Phase I, Open-label, Multi-center Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Varying Degrees of Renal Function
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
To assess the effect of varying degrees of renal function as defined by creatinine clearance), on the pharmacokinetics of panobinostat.
First 7 days
United States: Food and Drug Administration
|University of Utah / Huntsman Cancer Institute||Salt Lake City, Utah 84103|